SEC Form 10-Q filed by aTyr Pharma Inc.
$ATYR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2025 | $16.00 | Outperform | Leerink Partners |
| 1/6/2025 | Overweight | Cantor Fitzgerald | |
| 10/4/2024 | $17.00 | Overweight | Wells Fargo |
| 9/5/2024 | $9.00 | Buy | Jefferies |
4 - aTYR PHARMA INC (0001339970) (Issuer)
4 - aTYR PHARMA INC (0001339970) (Issuer)
Leerink Partners initiated coverage of aTyr Pharma with a rating of Outperform and set a new price target of $16.00
Cantor Fitzgerald initiated coverage of aTyr Pharma with a rating of Overweight
Wells Fargo initiated coverage of aTyr Pharma with a rating of Overweight and set a new price target of $17.00